Cumulative evidence shows that GLP-1 exerts direct and beneficial effects on hepatocytes to protect against the progression of NAFL to NASH, suggesting that GLP-1 could be a novel therapy for NASH14–17. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.